Four RPB-supported researchers and a Scientific Advisory Panel member have been honored with the prestigious 2018 António Champalimaud Vision Award for their groundbreaking research
The first patient receives an FDA-approved gene therapy for inherited retinal disease at Mass. Eye and Ear.
RPB-supported researchers made a critical discovery about the gene mutation that causes many retinal degenerative diseases, opening the door for a new line of research into potential treatments.
Findings raise the possibility of treating blinding eye diseases using a patient's own corrected cells as replacement tissue
New method for delivering corrective genes to restore energy production in cells could have wide application.
Findings indicate that retinitis pigmentosa is treatable even at advanced disease stages.
The Neitzes are internationally recognized for developing a potential gene therapy cure for color blindness and are among the world’s thought leaders on genetic and environmental factors that may be influencing a global epidemic of myopia...
|General Info||Grants||News & Resources|